Prevention of irinotecan plus5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer
Open Access
- 1 May 2003
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 14 (5) , 805-806
- https://doi.org/10.1093/annonc/mdg193
Abstract
Irinotecan (CPT-11) plus 5-fluorouracil/leucovorin (5-FU/LV) regimen is at present employed as first-line chemotherapy for advanced colorectal cancer (CRC). Its clinical use is associated with an elevated incidence of diarrhoea (∼60–70%). Diarrhoea is the dose-limiting toxicity of this regimen and sometimes represents a serious adverse event [1]. Recently, the role of the intestinal bacterial microflora in the etiopathogenesis of the CPT-11-induced intestinal toxicity has been discovered. The active metabolite of CPT-11, SN38, is generated from CPT-11 by sieric carboxylesterase, and subsequently conjugated to SN38-G by hepatic UDP-glucuronyltransferase. SN38-G is the inactive metabolite of CPT-11 and is excreted into the small intestine, from which it is eliminated in the faeces [2].Keywords
This publication has 1 reference indexed in Scilit:
- Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in ratsCancer Chemotherapy and Pharmacology, 1998